Clinical Trial Update: Egcg, a dyrk1a Inhibitor as Therapeutic Tool for Reversing Cognitive Deficits in Down Syndrome Individuals. [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating EGCG, a DYRK1A inhibitor, as a potential therapy to reverse cognitive deficits in individuals with Down syndrome, has comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Down Syndrome

Drugs mentioned

• EGCG (epigallocatechin gallate)

Snippet

Sponsor: Parc de Salut Mar | Conditions: Down Syndrome | Phase 2 | Status: COMPLETED